Breast cancer is the most commonly diagnosed cancer globally, with over 2.3 million new cases annually. Treatment is increasingly guided by receptor subtype, HR+/HER2−, HER2+, and triple-negative, with targeted therapies, CDK4/6 inhibitors, antibody-drug conjugates, and immunotherapy reshaping outcomes in both early and metastatic settings. Polygenic risk testing and ctDNA-based monitoring are poised to further personalise care pathways.
ADCs Advance First-Line TNBC Treatment, Improving PFS
Antibody-drug conjugates are improving progression-free survival in first-line triple-negative breast cancer, offering new options for patients.
Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.
Tucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Tucatinib demonstrated extended progression-free survival in HER2-positive breast cancer with a consistent safety profile, reinforcing its role.
Breast Cancer in Transgender Individuals: More Research Needed
Current literature on breast cancer in transgender and gender-diverse individuals is limited, highlighting a need for more inclusive research and care strategies.
GLP-1 Agonists: Less Weight Loss, Possible Breast Cancer Survival
GLP-1 receptor agonists, while not primarily indicated for oncology, show potential for survival benefits in breast cancer patients.
Metastatic ILC Survival Varies by Mutational Signature
Survival outcomes in metastatic invasive lobular carcinoma (ILC) differ based on specific mutational signatures, impacting treatment stratification.
T-DXd Side Effects in Breast Cancer Warrant Continued Attention
Clinicians must maintain vigilance for adverse events associated with trastuzumab deruxtecan (T-DXd) in breast cancer, particularly interstitial lung disease.
Comprehensive Care Improves Outcomes for CAYA Cancer Survivors
Comprehensive, multidisciplinary care models are essential for childhood, adolescent, and young adult (CAYA) cancer survivors to mitigate long-term sequelae.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12